Leora Horn, M.D., M.Sc., associate professor of Medicine and clinical director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center (VICC), has been selected to lead a clinical research trial of combination therapy using two targeted drugs for the treatment of a specific form of lung cancer.

DS Services of America Inc. recently presented a $100,000 gift to Vanderbilt-Ingram Cancer Center (VICC) to support breast cancer research.

A novel fluorescent nanobeacon can distinguish normal from diseased colon tissue, potentially offering advantages for colorectal cancer screening.

Several investigators in Vanderbilt-Ingram Cancer Center’s (VICC) Breast Cancer Program have received grant awards to support translational research that may improve disease outcomes for patients.

Despite dramatic recent advances in treatment, colorectal cancer killed more than 49,000 Americans last year, according to the National Cancer Institute, making it the second most lethal malignancy after cancers of the lung and bronchus.

Faced with the negative quality-of-life effects from surgery and radiation treatments for prostate cancer, low risk patients may instead want to consider active surveillance with their physician, according to a study released Tuesday by the Journal of the American Medical Association (JAMA).

Vanderbilt investigators have discovered that activated epidermal growth factor receptor may be a target for therapies to prevent colorectal cancer development.